[3] Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023 Nov 25;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1. Epub 2023 Sep 22. PMID: 37748491.链接：https://pubmed.ncbi.nlm.nih.gov/37748491/ [4]Wang W, He S, Zhang W,...
当CD19 CAR-T治疗失败时,CD22就成为了候选靶点。 2022年3月,Experimental Hematology & Oncology期刊上发表了题为“A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patie...
2023年,Cancer Communications期刊上发表了题为“Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy”的研究论文,旨在探究局部治疗加CAR-GPC3 T细胞治疗是否对晚期肝细胞癌患...
[1] Long-term outcomes following CAR T cell therapy: what we know so far https://www.nature.com/articles/s41571-023-00754-1 [2] T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.https://pubmed.ncbi.nlm.nih.gov/27412889/ ...
[1]Qi C,et al.CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. J Hematol Oncol.2023 Sep 9;16(1):102.https://pubmed.ncbi.nlm.nih.gov/37689733/ [2]Qi C,et al.Claudin18. 2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results[...
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and availa
虽然目前CAR-T疗法在血液癌症之外的领域还未进入大规模临床使用阶段。不过，多项研究已经证实其在临床上的强大潜力，相信在不久的将来，CAR-T疗法可以作为人们面对多种疾病时的又一选择！参考文献：[1] Verma M, Obergfell K, Topp S, Panier V, Wu J. The next-generation CAR-T therapy landscape. Nat ...
题目：Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs 期刊：Molecular Therapy【影响因子12.1】链接：pubmed.ncbi.nlm.nih.gov/34091054/ 这篇文章由宾大Weissman与mRNA领头企业Acuitas Therapeutic合作发表。研究报道了将CD4抗体与LNP偶联可实现对CD4+...
CAR-T疗法是如何起作用的 T细胞是人体重要的免疫细胞，可以直接杀死感染细胞或癌细胞，并激活免疫反应。
“我们虽然无法预测未来，但更期待CAR-T疗法为更多患者带来生的希望。”这也是众多参与CAR-T研究的科学家们共同的心声。End 参考文献：1. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or ...